ClinicalTrials.gg
RecruitingNCT06593665RPLNDUpdated Feb 13, 2026

Intrathecal Morphine Versus Intravenous Methadone for Postoperative Analgesia Following Retroperitoneal Lymph Node Dissection.

A Phase 3 interventional study of Inrathecal Morphine and Intravenous Methadone in Testicular Cancer, sponsored by Indiana University. Recruiting at 2 sites in United States. Open to male participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-02-13.

Sponsored by Indiana University · Phase 3, Interventional, and Other

How we know

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
142
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 167 studies in Testicular Neoplasms with a site in United States — 21 open to participants now, 26 under way, 1 of them phase 3. Testicular Neoplasms · United States.

Planned enrollment
19th of 111
142 · median 36
Started
2024
with 5 others
Phase 3
16 of 167
1 open now
Primary completion
2026-12
later than 4 of 25 live
Registered
153rd of 167
by date

Among the 167 studies in Testicular Neoplasms with a site in United States, this one is the 19th largest by planned enrollment of the 111 interventional ones that give a count, is one of 6 that started in 2024, is one of 16 in phase 3, reaches primary completion later than 4 of the 25 other live ones, and was the 153rd registered.

Testicular Neoplasms

295 studies on the registry are indexed under Testicular Neoplasms; 51 are open to participants now.

Browse Testicular Neoplasms studies →

Open to participants now

21 of the 167 studies in Testicular Neoplasms with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 Testicular Neoplasms studies recruiting now, 26 (60%) set no upper age limit and 11 (26%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 80 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 167 studies in Testicular Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This randomization study is to compare both intrathecal morphine and intravenous methadone, which are both standard of care, for pain management in patients undergoing retroperitoneal lymph node dissections for primary testicular cancer. Investigators plan to compare their analgesic effectiveness at different postoperative time intervals.

Read the detailed description

In this study, investigators aim to compare intravenous methadone combined with standard multimodal analgesia and surgical infiltration of local anesthesia to intrathecal duramorph with standard multimodal analgesia and surgical infiltration of local anesthesia. In this single blinded prospective randomized control trial, investigators hypothesize that intravenous methadone will provide a significant reduction in patient opioid consumption when compared to intrathecal opioid analgesia in the first 24 hours in patients who undergo PC/RPLND.

03

Conditions studied

  • Testicular Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients undergoing a virgin (chemotherapy has not been used) or post- chemotherapy retroperitoneal lymph node dissection for primary testicular cancer at IU Health AAHC
  • ASA Class 1, 2, 3
  • Age 18 to 80 years; Male
  • less than 50kg/m2

Exclusion criteria

Exclusion Criteria:

  • Any for neuraxial analgesia
  • Patient on home methadone at any dose
  • Any physical, mental or medical conditions which, in the opinion of the investigators, may confound quantifying postoperative pain resulting from surgery.
  • Known true allergy to the study medications (morphine, bupivacaine, acetaminophen, methadone)
  • Any history of substance abuse in the past 6 months which would include heroin or any other illegal street drugs
  • End stage liver disease, end stage renal disease
  • Patient staying intubated after surgery
  • Patient (home dose) taking more than 30mg PO morphine equivalent (PME) per day
  • Any additional surgical procedures to the patient with a different surgical incision compared to the standard laparotomy for the RPLND procedure, i.e. thoracic tumor reduction
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
142 participants (estimated)

Study arms

  • Other
    Intrathecal Morphine

    Intrathecal preservative free morphine (duramorph) 200 mcg with 7.5mg of hyperbaric bupivacaine placed by a spinal needle prior to induction of general anesthesia (n=71)

    Drug: Inrathecal Morphine

  • Other
    Intravenous Methadone

    Intravenous methadone dosed at 0.2 mg/kg Ideal Body weight up to a maximum dose of 20mg, rounded to the nearest milligram, for all patients given during the induction of general anesthesia (n=71)

    Drug: Intravenous Methadone

Interventions

  • DrugInrathecal Morphine

    Intrathecal preservative free morphine (duramorph) 200 mcg with 7.5mg of hyperbaric bupivacaine placed by a spinal needle prior to induction of general anesthesia (n=71)

  • DrugMethadoneStudies of MethadoneMethadone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Intravenous methadone dosed at 0.2 mg/kg Ideal Body weight up to a maximum dose of 20mg, rounded to the nearest milligram, for all patients given during the induction of general anesthesia (n=71)

06

What researchers measure

Primary outcomes

  1. IV morphine equivalent (MME)

    Cumulative Milligrams of morphine equivalent (MME) consumption

    Time frame: First 24 hours postoperative

Secondary outcomes

  1. Opioid consumption

    Opioid consumption in morphine equivalent (MME)

    Time frame: 1 hour after arrival time to post anesthesia care unit

  2. Opioid consumption

    Opioid consumption in morphine equivalent (MME)

    Time frame: 12 hours after arrival time to post anesthesia care unit

  3. Opioid consumption

    Opioid consumption in morphine equivalent (MME)

    Time frame: 24 hours after arrival time to post anesthesia care unit

  4. Opioid side effect-Nausea

    Incidence of opioid side effects-nausea

    Time frame: after arrival time to post anesthesia care unit until 24 hours/completion of study

  5. Opioid side effects-Vomiting

    Incidence of opioid side effects-vomiting

    Time frame: after arrival time to post anesthesia care unit until 24 hours/completion of study

  6. Opioid side effects-Pruritis

    Incidence of opioid side effects-pruritis

    Time frame: after arrival time to post anesthesia care unit until 24 hours/completion of study

  7. Adverse Events

    Incidence of adverse events

    Time frame: after arrival time to post anesthesia care unit until 24 hours/completion of study

  8. Opioid side effects-Respiratory Depression

    Incidence of opioid side effects-respiratory depression

    Time frame: after arrival time to post anesthesia care unit until 24 hours/completion of study

  9. Pain Scores

    Visual Analog Scale (VAS) pain score On a scale of 1 to 10 (increments of 1 unit), 1 being no pain at all, 10 being the most pain the patient has ever experienced

    Time frame: 24 hours after arrival time to post anesthesia care unit

  10. Pain Scores

    Visual Analog Scale (VAS) pain score On a scale of 1 to 10 (increments of 1 unit), 1 being no pain at all, 10 being the most pain the patient has ever experienced

    Time frame: 12 hours after arrival time to post anesthesia care unit

07

Study locations

2 of 2 sites recruiting
  • Indiana Univeristy
    Indianapolis, Indiana 46202, United States
    Recruiting
  • Indiana University Hospital
    Indianapolis, Indiana 46202, United States
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2024 (actual). Primary completion is estimated for Dec 2026, 27 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2024
First posted
Sep 19, 2024
StartActual
Sep 10, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Feb 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06593665
Lead sponsor
Indiana University
Responsible party
Kevin Michael Backfish-White, MD (Dept. of Anesthesiology, Asst. Professor, Indiana University) — Principal investigator
First posted
Sep 19, 2024
Start date
Sep 10, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Feb 13, 2026

Study contacts

Lyla S Farlow
Contact
lychrist@iu.edu
3179489804
Angie Plummer
Contact
plummera@iu.edu
3179447293
Gulraj S Chawla, MD
principal investigator · Indiana University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methadone

Start the discussion